XM does not provide services to residents of the United States of America.

S
S

Sanofi

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Reuters - 2 days ago

US urges makers of infant RSV shots to meet winter demand

UPDATE 2-US urges makers of infant RSV shots to meet winter demand Adds details on Thermo Fisher in paragraph 7 Dec 7 (Reuters) - U.S. officials met with manufacturers of the infant and toddler RSV immunization Beyfortus this week seeking to boost access to the shot, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week .
A
S
T
Reuters - 2 days ago

US urges RSV vaccine makers to meet winter demand, White House says

US urges RSV vaccine makers to meet winter demand, White House says WASHINGTON, Dec 7 (Reuters) - U.S. officials met again with RSV vaccine manufacturers this week amid ongoing efforts to boost access to the shots, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week . The officials on Tuesday met with representatives of Sanofi SA SASY.PA , AstraZeneca AZN.L and Thermo Fisher TMO.N "and urged them to work expeditiously to me
A
S
T
Reuters - 2 days ago

Sanofi to boost drug development spend by 700 mln euros in 2024

Sanofi to boost drug development spend by 700 mln euros in 2024 FRANKFURT, Dec 7 (Reuters) - Sanofi said it would spend close to 700 million euros ($754 million) more on drugs development next year, specifying for the first time an increase in costs that roiled investors and triggered a sell-off in the stock in late October. Speaking on a media call ahead of an R&D investor event in New York on Thursday, CEO Paul Hudson said that a "steady state" of longer-term development expenses was likely be
S
Reuters - 2 days ago

European shares slip after recent rally, economic worries weigh

UPDATE 2-European shares slip after recent rally, economic worries weigh For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window German industrial output falls unexpectedly in October Iberian banks slide, broker flags chance of earlier rate cuts Games Workshop slumps on weak licensing forecast STOXX 600 off 0.3%, Germany's DAX slips 0.2% Updated at 1700 GMT By Khushi Singh, Ankika Biswas and Bansari Mayur Kamdar Dec 7 (Reuters) - European shares
B
B
C
L
S
T
A
E
F
U
G
Reuters - 2 days ago

European shares dip on economic woes; travel and leisure lead losses

European shares dip on economic woes; travel and leisure lead losses For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Dec 7 (Reuters) - European shares dropped on Thursday, led by travel and leisure stocks, as investors grew wary of an economic downturn following a slew of recent weak data out of Germany and keenly awaited a GDP print from the euro zone.
L
S
E
F
U
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.